Women’s Health Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Drugs (Prolia, Xgeva, Evista, Mirena, Zometa, Others), By Application (Female Infertility, Post enopausal Osteoporosis, Endometriosis, Contraception, Others), By Region and Competition 2021-2031F

Forecast Period	2027-2031
Market Size (2025)	USD 16.76 Billion
CAGR (2026-2031)	7.24%
Fastest Growing Segment	Female Infertility
Largest Market	North America
Market Size (2031)	USD 25.49 Billion

Market Overview

The Global Women’s Health Market will grow from USD 16.76 Billion in 2025 to USD 25.49 Billion by 2031 at a 7.24% CAGR. The Global Women’s Health Market encompasses a comprehensive suite of pharmaceuticals, medical devices, and diagnostic tools specifically engineered to address conditions that exclusively or disproportionately affect women, such as reproductive health issues, gynecological cancers, and autoimmune diseases. A primary driver fueling this sector is the escalating burden of chronic pathologies alongside an aging female demographic, which necessitates sustained clinical intervention and long-term management strategies. According to the American Cancer Society, in 2024, an estimated 310,720 new cases of invasive breast cancer were expected to be diagnosed among women in the United States. This data underscores the critical, non-discretionary demand for advanced therapeutic and diagnostic solutions, establishing a robust foundation for market growth that operates independently of transient technological trends.

Despite these strong growth indicators, the market confronts a significant impediment in the form of historical funding disparities and complex regulatory landscapes. Research and development for female-specific biology have frequently received lower capital investment compared to other therapeutic areas, creating a bottleneck for innovation. This lack of equitable resource allocation, combined with the high cost of clinical trials, complicates the pathway to commercialization for novel treatments. Consequently, these financial and regulatory headwinds threaten to decelerate the introduction of essential healthcare solutions, thereby challenging the market's capacity to fully expand and meet the diverse needs of the global patient population.

Key Market Drivers

The proliferation of FemTech and digital health innovations serves as a primary catalyst for market expansion, fundamentally altering how reproductive and general care is delivered. This sector growth is characterized by the integration of artificial intelligence and mobile connectivity to provide personalized solutions for menstruation tracking, fertility management, and menopause support. These technologies bridge the access gap, empowering patients with real-time health data and reducing reliance on traditional clinical settings. According to General Atlantic, July 2024, in the 'Flo Health Secures $200 Million Series C Investment' press release, the digital health platform raised over $200 million in capital to enhance its predictive capabilities and expand user reach. Such substantial capital infusion validates the commercial viability of direct-to-consumer digital tools, indicating a shift where technological scalability becomes a core component of women's healthcare infrastructure.

Favorable government policies and increased funding allocations for women’s healthcare research act as a critical stabilizer and accelerator for the industry. Historic underfunding is being actively countered by state-sponsored initiatives designed to de-risk early-stage research and incentivize private sector participation in neglected areas like endometriosis and maternal health. According to the Advanced Research Projects Agency for Health, February 2024, in the 'ARPA-H Launches Sprint for Women’s Health' announcement, the agency committed $100 million to fund novel research and development specifically for female health outcomes. This influx of non-dilutive funding allows companies to pursue high-risk, high-reward therapeutic pipelines that were previously deemed financially unfeasible. The broader economic implications of these policy shifts are profound; according to the World Economic Forum, in 2024, closing the gender health gap could potentially boost the global economy by $1 trillion annually by 2040, further motivating systemic investment.

Download Free Sample Report

Key Market Challenges

Historical funding disparities significantly impede the progress of the women's health market by restricting the flow of capital necessary for research and development. This lack of equitable financial resource allocation creates a bottleneck for innovation, making it difficult for pharmaceutical and medical device companies to advance novel treatments through costly clinical trials. Consequently, the development of therapies for conditions specific to female biology faces substantial delays, limiting the availability of effective management strategies for chronic pathologies.

The impact of this underinvestment is evident in the disproportionately low share of global research funding dedicated to this sector. According to the World Economic Forum, in 2024, only 1 percent of the total healthcare research and development investment was directed toward female-specific conditions beyond oncology. This minimal financial commitment hampers the ability of the market to diversify its portfolio and address unmet medical needs. As a result, the sector struggles to reach its full commercial potential while leaving a significant portion of the global patient population without adequate therapeutic options.

Key Market Trends

The Proliferation of At-Home Diagnostic Testing for Reproductive and Hormonal Health is fundamentally restructuring the diagnostic landscape by decentralizing care and addressing barriers related to clinical access. This trend is driven by a growing demand for privacy and convenience, enabling patients to perform critical health screenings, such as those for cervical cancer and sexually transmitted infections, within their own homes. The shift towards self-collection methods significantly improves compliance rates among under-screened populations who may avoid traditional pelvic exams due to discomfort or logistical constraints. According to Labcorp, April 2025, in the 'Labcorp to Offer HPV and STI Self-Collection Options' press release, the company introduced a nationwide FDA-approved solution enabling women to self-collect vaginal specimens for HPV testing, directly targeting the significant portion of the population that is not up to date with recommended screenings.

The Development and Commercialization of Non-Hormonal Contraceptive Innovations is emerging as a critical market force, responding to the increasing patient preference for family planning methods that avoid the physiological side effects of hormonal regimens. This trend focuses on the engineering of long-acting reversible contraceptives (LARCs) that utilize advanced materials and designs to provide high efficacy without systemic hormonal intervention. These innovations offer a necessary alternative for women who are contraindicated for or dissatisfied with hormonal options, thereby expanding the total addressable market for contraceptive devices. According to Sebela Pharmaceuticals, January 2025, in the 'Sebela Women’s Health Announces Publication of Phase 3 Pivotal Study Results' announcement, their investigational hormone-free Copper 175mm2 IUD demonstrated a 1-year Pearl Index of 0.94, validating the effectiveness of these novel non-hormonal solutions in a clinical setting.

Segmental Insights

Based on recent market intelligence, the Female Infertility segment is currently the fastest-growing category within the Global Women’s Health Market. This rapid expansion is primarily driven by shifting societal patterns, specifically the global trend toward delayed childbearing, which often necessitates medical intervention for conception. Furthermore, the rising prevalence of reproductive disorders such as Polycystic Ovary Syndrome (PCOS), as noted by the World Health Organization, has significantly amplified the need for specialized care. Consequently, the increasing adoption of Assisted Reproductive Technology (ART) and advanced diagnostic services is fundamentally propelling this segment’s accelerated development.

Regional Insights

North America leads the Global Women’s Health Market, driven by the rising prevalence of chronic conditions such as osteoporosis and breast cancer among the female population. This dominance is supported by a developed healthcare infrastructure and favorable reimbursement frameworks that improve patient access to essential care. Additionally, the strong presence of key pharmaceutical manufacturers fosters continuous product innovation. The frequent approval of new therapies by the U.S. Food and Drug Administration (FDA) further accelerates market expansion, ensuring the region sustains its primary market position.

Recent Developments

• In July 2025, Twentyeight Health, a digital-first healthcare provider, launched its Personalized Care Program to evolve into a comprehensive women's health platform. The company introduced three new virtual services, including on-demand prescription consultations for common health needs, medically guided weight management, and medical-grade skincare plans. This expansion was designed to address significant disparities in the healthcare system by ensuring convenient, judgment-free access to care for women regardless of their income or coverage status. The initiative marked a strategic shift for the company, moving beyond reproductive care to prioritize personalized, holistic health solutions over transactional medical guidance.
• In March 2025, Bayer presented pivotal Phase III research results for its investigational compound, elinzanetant, at the 16th Congress of the European Society of Gynecology. The data demonstrated the efficacy and safety of the non-hormonal treatment for moderate to severe vasomotor symptoms associated with menopause. The presentation included pooled analyses from clinical studies and highlighted findings on the impact of sleep disturbances on women's quality of life. This breakthrough research underscored the company's ongoing commitment to advancing science in women's healthcare and broadening therapeutic options for unmet medical needs in menopause management.
• In March 2024, Organon entered into a collaboration with Flat6Labs to launch the second cycle of the Women’s Health Accelerator Program. This strategic partnership aimed to support and scale early-stage digital health startups focused on women’s health across the Middle East, North Africa, and Turkey. The program was designed to provide entrepreneurs with an intensive curriculum, strategic mentorship, and business training to build innovative products in areas such as family planning and fertility. The initiative reflected the company's dedication to fostering digital solutions that address pressing healthcare challenges and improve wellness outcomes for women globally.
• In March 2024, Perrigo Company plc announced the official retail launch of Opill, the first daily oral contraceptive approved for use without a prescription in the United States. The product was shipped to major pharmacies and retailers nationwide and made available for online purchase, significantly expanding access to birth control for women of all ages. The company introduced the product with a suggested retail price for one-month and three-month supplies to ensure affordability. This launch represented a major breakthrough in the women’s health market, establishing a new consumer self-care category for contraceptive access.

Key Market Players

• AbbVie, Inc
• Bayer AG
• Merck & Co., Inc
• Pfizer, Inc
• Teva Pharmaceutical Industries Ltd
• Amgen, Inc
• Apothecus Pharmaceutical Corp
• Blairex Laboratories, Inc
• Ferring B.V.
• Agile Therapeutics

By Drugs	By Application	By Region
Prolia Xgeva Evista Mirena Zometa Others	Female Infertility Post enopausal Osteoporosis Endometriosis Contraception Others	North America Europe Asia Pacific South America Middle East & Africa

Report Scope:

In this report, the Global Women’s Health Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Women’s Health Market, By Drugs:

• Prolia
• Xgeva
• Evista
• Mirena
• Zometa
• Others

• Women’s Health Market, By Application:

• Female Infertility
• Post enopausal Osteoporosis
• Endometriosis
• Contraception
• Others

• Women’s Health Market, By Region:

• North America
• United States
• Canada
• Mexico
• Europe
• France
• United Kingdom
• Italy
• Germany
• Spain
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• South America
• Brazil
• Argentina
• Colombia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE